Founded by Dr. Prasad Konkalmatt, an AAV gene therapy scientist with extensive academic and industry experience, AAVion is developing technologies to enable delivery of genes beyond the conventional AAV packaging capacity.

Our core innovations include

Proprietary technologies enabling delivery of genes beyond the conventional ~4.7 kb AAV packaging limit

Next-generation capsid technologies designed to improve tissue targeting and delivery efficiency